Xiangxiang Ma, a partner of Anjie Broad Law Firm, explores the various ways in which a recent U.S. executive order on drug pricing is impacting Chinese pharmaceutical companies’ license-out model
Chinese EV giant BYD investigated in U.S. for alleged ties to Chinese Communist Party; European companies more pessimistic about doing business in China amid economic slowdown; and the world’s first intergovernmental legal organization for mediation established in Hong Kong
Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
SAMR adds new forms in which illegal acts of abusive administrative power to eliminate or restrict competition manifest, and clarifies the “appropriate confidentiality measures” in trade secrets protection. Permanent supplementation of working capital constitute a change in the purpose of offering proceeds
Globally, the accelerating spread of AI shows no sign of abating, and laws and regulations are under greater pressure to keep up. Wenpei Yu and Yunsi Hu of Lifeng Partners, together with Dr. Anja Geller of Redeker Sellner Dahs, provide an overview of the similarities and differences between the approaches taken in the EU and China, and what the future may hold.
CATL and Ant Group’s planned listings could break recent HK IPO records; The lowering of U.S. drug prices will impact Chinese drugmakers; and U.S. House passes sanctions bill targeting trade secret theft by China.
